ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia

BOSTON, May 02, two thousand seventeen (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on fresh immunotherapies, today announced that an investigator-initiated Investigational Fresh Drug (IND) application to the U.S. Continue reading →